N4 Pharma PLC Investor Presentation via Investor Meet Company
09 Outubro 2023 - 3:00AM
RNS Non-Regulatory
TIDMN4P
N4 Pharma PLC
09 October 2023
Reach Non-regulatory
9 October 2023
N4 Pharma Plc
("N4 Pharma" or the "Company")
Investor Presentation via Investor Meet Company
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company
developing Nuvec(R), a novel delivery system for oncology, gene
therapy and vaccines, is pleased to announce that Nigel Theobald
(CEO) and Paul Murray (Nanogenics) will provide an update following
the Company's acquisition of Nanogenics via a live presentation on
the Investor Meet Company platform on 16 October 2023 at 2.00pm
BST.
The presentation is open to all existing and potential
shareholders. Questions can be submitted pre-event via your
Investor Meet Company dashboard up until 9.00am the day before the
meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add
to meet N4 Pharma Plc via:
https://www.investormeetcompany.com/n4-pharma-plc/register-investor
Investors who already follow N4 Pharma Plc on the Investor Meet
Company platform will automatically be invited.
Enquiries:
N4 Pharma Plc Via IFC Advisory
Nigel Theobald, CEO
Luke Cairns, Executive Director
SP Angel Corporate Finance LLP Tel: + 44 (0)20 3470 0470
Nominated Adviser and Joint Broker
Matthew Johnson/Kasia Brzozowska
(Corporate Finance)
Vadim Alexandre/Rob Rees (Corporate
Broking)
Turner Pope Investments (TPI) Limited Tel: +44 (0)20 3657 0050
Joint Broker
Andy Thacker
IFC Advisory Limited Tel: +44 (0)20 3934 6630
Financial PR
Graham Herring
Zach Cohen
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a
novel delivery system for oncology, gene therapy and vaccines using
its unique silica nanoparticle delivery system called Nuvec(R).
N4 Pharma's business model is to partner with companies
developing novel antigens in these fields to use Nuvec(R) as the
delivery vehicle for these antigens. As these products progress
through pre-clinical and clinical programs, N4 Pharma will seek to
receive upfront payments, milestone payments and ultimately royalty
payments once products reach the market.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAMFBBTMTTMBAJ
(END) Dow Jones Newswires
October 09, 2023 02:00 ET (06:00 GMT)
N4 Pharma (LSE:N4P)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
N4 Pharma (LSE:N4P)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024